AZN Breathes Easy, EXEL Scores FDA Nod, SRPT Disappointed, PETX On The Rise

The FDA panel has voted down Sarepta Therapeutics Inc.'s (SRPT) Eteplirsen, proposed for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping.

from RTT - Biotech http://ift.tt/24hfZtQ
via IFTTT